F0175000
Flucytosine
European Pharmacopoeia (EP) Reference Standard
Sign Into View Organizational & Contract Pricing
All Photos(1)
5-Fluorocytosine, 4-amino-5-fluoro-2(1H)-pyrimidinone, Flucytosine
C4H4FN3O
Recommended Products
grade
pharmaceutical primary standard
API family
flucytosine
manufacturer/tradename
EDQM
mp
298-300 °C (dec.) (lit.)
application(s)
pharmaceutical (small molecule)
format
neat
storage temp.
2-8°C
SMILES string
NC1=NC(=O)NC=C1F
InChI
1S/C4H4FN3O/c5-2-1-7-4(9)8-3(2)6/h1H,(H3,6,7,8,9)
InChI key
XRECTZIEBJDKEO-UHFFFAOYSA-N
Looking for similar products? Visit Product Comparison Guide
General description
This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.
Application
Flucytosine EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.
Biochem/physiol Actions
Nucleoside analog that has antifungal activities. 5-FC is deaminated by cytosine deaminase to product 5-fluorouracil, resulting in RNA miscoding. 5-Fluorocytosine inhibits DNA and RNA synthesis and interferes with ribosomal protein synthesis.
Packaging
The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.
Other Notes
Sales restrictions may apply.
related product
Certificates of Analysis (COA)
Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
Customers Also Viewed
Mayo Clinic proceedings, 73(12), 1205-1225 (1998-12-30)
Traditionally, amphotericin B has been the cornerstone of antifungal treatment. Toxicity, however, is a major dose-limiting factor of amphotericin B deoxycholate. Nevertheless, it continues to have a major role in the treatment of deep-seated mycotic infections. Recently, less nephrotic lipid
Pediatric nephrology (Berlin, Germany), 19(7), 801-804 (2004-06-03)
Bilateral fungal obstruction of the renal collecting system is rare in infancy. Treatment options include medical or surgical procedures. Reports of successful medical treatment with liposomal amphotericin B have been published but the duration of treatment is controversial. We report
Annales de biologie clinique, 45(6), 669-672 (1987-01-01)
The antimycotic and pharmacological properties of 5-fluorocytosine are presented. Especially the aspect of good gastrointestinal absorption, elimination by the kidney, unwanted side effects and appearance of primary and secondary resistance are discussed. The indication of 5 FC monotherapy or combination
Clinics in laboratory medicine, 7(3), 541-544 (1987-09-01)
Monitoring of flucytosine (5-FC) concentration in serum is of great importance. It may be anticipated that demand for this service will increase in the near future, because this drug is used in situations involving immunocompromised patients, including those afflicted with
Chemotherapy, 40(4), 287-289 (1994-07-01)
A case of Rhodotorula fungemia in a 13-year-old boy after neurosurgery successfully treated with miconazole and 5-flucytosine is reported. Intravascular catheter insertion, broad-spectrum anti-miocrobials, surgery, and immunosuppression are the main risk factors for fungemia.
Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.
Contact Technical Service